Table 3.
ASFA category I renal indications for therapeutic plasma exchange
| Kidney Disease | Indication | Reported RCTs |
|---|---|---|
| ANCA-associated rapidly progressive GN | Dialysis dependence or diffuse alveolar hemorrhage | 8 |
| Anti-GBM disease | Diffuse alveolar hemorrhage or dialysis independence | 1 |
| Cryoglobulinemia | Symptomatic, severea | 0 |
| FSGS | 0 | |
| Atypical hemolytic uremic syndrome | Factor H antibodies | 0 |
| Kidney transplant | ABO compatible; antibody-mediated rejection | 3 |
| Desensitization; living donor with positive cross-match | 0 | |
| ABO incompatible; desensitization; live donor | 0 | |
| Thrombotic thrombocytopenic purpura | 7 | |
| Drug-associated thrombotic microangiopathy | Ticlopidine | 0 |
Data are the numbers of randomized clinical trials reported, according to the 2013 ASFA guidelines (5). AFSA, American Society for Apheresis; RCT, randomized controlled trial; GBM, glomerular basement membrane.
a
One randomized clinical trial with immunoadsorption apheresis